Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia Journal Article
| Authors: | Chung, S. S.; Kim, E.; Park, J. H.; Chung, Y. R.; Lito, P.; Teruya-Feldstein, J.; Hu, W.; Béguelin, W.; Monette, S.; Duy, C.; Rampal, R.; Telis, L.; Patel, M.; Kim, M. K.; Huberman, K.; Bouvier, N.; Berger, M. F.; Melnick, A. M.; Rosen, N.; Tallman, M. S.; Park, C. Y.; Abdel-Wahab, O. |
| Article Title: | Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia |
| Abstract: | Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder characterized by somatic BRAFV600E mutations. The malignant cell in HCL has immunophenotypic features of a mature B cell, but no normal counterpart along the continuum of developing B lymphocytes has been delineated as the cell of origin. We find that the BRAFV600E mutation is present in hematopoietic stem cells (HSCs) in HCL patients, and that these patients exhibit marked alterations in hematopoietic stem/progenitor cell (HSPC) frequencies. Quantitative sequencing analysis revealed a mean BRAFV600E-mutant allele frequency of 4.97% in HSCs from HCL patients. Moreover, transplantation of BRAFV600E-mutant HSCs from an HCL patient into immunodeficient mice resulted in stable engraftment of BRAFV600E-mutant human hematopoietic cells, revealing the functional self-renewal capacity of HCL HSCs. Consistent with the human genetic data, expression of BRaf V600E in murine HSPCs resulted in a lethal hematopoietic disorder characterized by splenomegaly, anemia, thrombocytopenia, increased circulating soluble CD25, and increased clonogenic capacity of B lineage cells - all classic features of human HCL. In contrast, restricting expression of BRafV600E to the mature B cell compartment did not result in disease. Treatment of HCL patients with vemurafenib, an inhibitor of mutated BRAF, resulted in normalization of HSPC frequencies and increased myeloid and erythroid output from HSPCs. These findings link the pathogenesis of HCL to somatic mutations that arise in HSPCs and further suggest that chronic lymphoid malignancies may be initiated by aberrant HSCs. |
| Keywords: | controlled study; human cell; sequence analysis; somatic mutation; clinical feature; nonhuman; mouse; gene; gene expression; anemia; thrombocytopenia; animal experiment; animal model; gene frequency; cell renewal; cell differentiation; mutational analysis; b lymphocyte; carcinogenesis; germinal center; engraftment; quantitative analysis; splenomegaly; hematopoietic stem cell; alloantigen; interleukin 2 receptor alpha; clonogenesis; braf gene; hairy cell leukemia; phase 2 clinical trial (topic); cell composition; vemurafenib; human; priority journal; article |
| Journal Title: | Science Translational Medicine |
| Volume: | 6 |
| Issue: | 238 |
| ISSN: | 1946-6234 |
| Publisher: | American Association for the Advancement of Science |
| Date Published: | 2014-05-28 |
| Start Page: | 238ra71 |
| Language: | English |
| DOI: | 10.1126/scitranslmed.3008004 |
| PROVIDER: | scopus |
| PUBMED: | 24871132 |
| PMCID: | PMC4501573 |
| DOI/URL: | |
| Notes: | Cited By (since 1996):1 -- Export Date: 1 August 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work